Latest Nasdaq News

Global X Management updates estimated distribution amounts for three ASX-listed ETFs ending April 2026, confirming Dividend Reinvestment Plan eligibility and key payment dates.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

Nova Minerals has sent out its Scheme Booklet to shareholders and warrantholders, setting the stage for a May 29 vote on its proposed move from Australia to the US. The Independent Expert backs the scheme, and directors recommend approval.

Chilwa Minerals confirmed a significant niobium discovery at its Nakombe target, progressing with dual diamond rig drilling and advancing a NASDAQ listing application. Heavy mineral sands resource work continues alongside a new ionic clay rare earth program.

St George Mining has expanded its Araxá rare earths-niobium resource by 75% to 70.91Mt at 4.06% TREO, positioning the project among the world’s largest carbonatite deposits. The company also acquired land for processing facilities and forged new downstream partnerships, supported by Minas Gerais state tax incentives.

Resolution Minerals has successfully produced high-grade tungsten concentrates from historical stockpiles at its Golden Gate mine, achieving a 19-fold upgrade and strong recovery rates using simple gravity separation techniques.

Cleo Diagnostics has kicked off a staged manufacturing program with Bio-Techne to produce ovarian cancer test kits, moving from clinical sample collection to analytical validation and FDA submission preparation.

American Tungsten & Antimony (ASX: AT4) has set up a Level 1 ADR program with Deutsche Bank, paving the way for its planned Nasdaq listing in Q2 2026 and opening U.S. dollar trading access for American investors.

IperionX has transitioned its Virginia titanium operations to continuous 24/7 production, ramping proprietary HAMR™ titanium powder output to 4.2 metric tons in March and targeting 200 tons per annum by the end of 2026. Alongside manufacturing capacity expansions and strong U.S. Department of War backing, the company advances its critical minerals project in Tennessee.

American Rare Earths is fast-tracking its Wyoming Halleck Creek rare earths project, defining a pilot plant pathway, advancing oxide to metal studies, and targeting a NASDAQ listing by year-end 2026.

CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.

Resolution Minerals has raised A$20 million in a strongly supported institutional placement to accelerate exploration and development at its US Horse Heaven Project, while preparing for a NASDAQ listing to boost its US market presence.